Introduction to PGS and PGD
Clinics around the world offer a range of genetic testing options that can be very helpful in having a successful IVF treatment with the end result of a newborn healthy child without a genetic disease but in some cases it is used for sex selection. The array of terms concerning the preimplantation genetic diagnosis and other embryo genetic tests however can be a wide and confusing subject. What are the differences between PGD, GGS, CCS? With this guide the genetic testing will have no secrets before you.
Preimplantation Genetic Testing
Preimplantation genetic testing is a broad concept of the genetic testing on embryos.
This is a procedure that involves removing one or more of the nuclei from the eggs or embryos in order to test the gene sequence or aneuploidy for mutations before they will be transferred into the uterus.
PGD – Preimplantation Genetic Diagnosis
The most common of the genetic testing terms is the Preimplantation genetic diagnosis (PGD). It is the most widely used as the whole broad concept that refers to any of the embryo genetic testing kinds.
PGD was developed in the end of the 1980s to be the alternative for couples which were at risk of passing genetic diseases on their offspring. Using this testing and IVF the couple is able to conceive using the embryos that were tested for genetic disorders before they are transferred into the uterus for implantation. This was and still is a great alternative to the prenatal diagnosis of the genetic disorder and a possible termination of the fetus.
Currently the term PGD is used for describing the testing for a particular genetic disease. Patients who have a high risk for transmitting a single-gene defect to their offspring are offered to do this specific test to avoid for example such diseases like haemophilia, cystic fibrosis or Tay-Sachs disease.
To put it simply those single gene disorders are genetic conditions which occur in the affected person’s DNA – because of the alteration or mutation of the specific gene in it. According to the Practice Committee of the Society for Assisted Reproductive Technology (SART) and the Practice Committee of the American Society for Reproductive Medicine (ASRM) this term is put in use if one or both of the parents carry the mutated gene or a balanced chromosomal rearrangement, then testing is being performed to determine whether this particular mutation or the unbalanced chromosomal complement was transmitted to the oocyte or embryo.
PGS – Preimplantation Genetic Screening
The newer term used to describe the embryo screening process to check if the number of chromosomes is correct and to check the chromosomes for structural abnormalities is the Preimplantation Genetic Screening (PGS) (also called aneuploidy screening). According to the SART and ASRM this term is used if it is known or presumed that the genetic parents are chromosomally normal and they are screened for aneuploidy.
It is said that women over 35, also women which had failed IVF procedures in the past or recurrent miscarriages have a higher success rate for IVF if they use PGS.
In the older technique of PGS, fluorescence in situ hybridization (FISH) was used (a method used to detect and localize the presence or absence specific DNA sequences on chromosomes) which was only able to analyze from 5 to 10 pairs of chromosomes out of the 23 pairs in a single cell. More current methods like single nucleotide polymorphism (SNP) or comparative genomic hybridization (CGH) allow to analyze all 23 pairs of chromosomes.
CCS – Comprehensive Chromosomal Screening
The term Comprehensive Chromosomal Screening (CCS) is used to describe a type of PGS – aneuploidy screening. 23 pairs of human chromosomes in a single cell can be evaluated with this method by using the quantitative polymerase chain reaction (qPCR), Single Nucleotide Polymorphism (SNP) or Comparative genomic hybridization (CGH).
Using CCS you can retrieve from 5 to 10 cells from a 5 or 6 day embryo. While waiting for the end result the embryo is frozen. Afterwards the embryo is thawed and transferred in a separate cycle. Followed by the day 5 embryo biopsy which has better accuracy and it significantly lowers the chances for potential damage which a biopsy could cause to the embryo which by then has couple hundreds of cells.
Conducting the biopsy on a 5 day embryo gives the advantage over the 3 day embryo because it already has not a single cell but a few more cells which gives you more material to work with. In theory the 5 day embryo might be more resistant to the test than a 3 day embryo.